Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided lisafoclax bridging to time-limited BTK inhibitor therapy in CLL
ChiCTR2600121895Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by West China Hospital of Sichuan University. Primary endpoint: MRD negative rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2600121895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121895.